Objectives: Some authors have advocated the daily use of sildena®l for prophylaxis against, or treatment of, erectile dysfunction. However, no information has been published to support such a dosage regimen. The safety pro®le of uninterrupted use of sildena®l has not been evaluated as it pertains to alteration of PDE type 6 in the retina. In the present study we investigated whether short-or long-term exposure to a variety of sildena®l doses affect the expression of an enzyme important in the normal phototransduction cascade. Methods: Sustained-release sildena®l pellets were implanted in 120-day-old male rats with concentrations from 1 ± 200 mg. Rat retinal tissue was harvested 7, 14, and 29 days after implantation. Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) using GAPDH as an endogenous internal standard was used to quantitate PDE type 6 gene expression. Results: Expression of PDE type 6 was upregulated after 7 days with dosages 5 mg (P`0.02). Signi®cant downregulation of PDE type 6 expression was ®rst noted with high dose sildena®l 14 days after implantation (P`0.02). Expression of PDE type 6 was signi®cantly and profoundly downregulated 29 days after implantation for all pellet formulations ! !10 mg (P`0.01). Conclusions: Sildena®l downregulates PDE type 6 expression in a dose-and time-dependent fashion. These ®ndings support the explanation that PDE type 6 inhibition causes the dosedependent clinical effects of visual disturbance in men taking sildena®l. Implications for longterm, daily use of sildena®l in men are not clear.
Introduction
Sildena®l is an orally active inhibitor of cyclic guanosine-3,5-monophosphate (cGMP) speci®c phosphodiesterase (PDE) type 5. This medication has proven effective for the treatment of a variety of patients with erectile dysfunction. 1 Generally, sildena®l is a well tolerated oral medication with relatively few severe adverse events. Visual disturbances occur in men with a frequency of 9 ± 11% in ®xed dosage studies of 100 mg, 1 ± 3 and as high as 40% in ®xed dosage studies of 200 mg. 3 The physiologic basis of this adverse event is presumed to be sildena®l's interference with retinal PDE type 6.
The retina is a tissue rich in PDE type 6, an enzyme which plays a key role in light signal transduction. The most abundant isoenzyme of PDE type 6 can be found in the membrane of retinal rod-speci®c photoreceptors. PDE type 6 is a tetrameric enzyme consisting of two catalytic subunit pairs and two inhibitory pairs. This enzyme functions to reduce intracellular cytoplasmic levels of cGMP in the retina. 4, 5 This regulation of retinal cGMP is an integral feature of the normal phototransduction cascade. Persistent elevation of retinal cGMP leads to rod photoreceptor vesiculation, degeneration and eventual cell death. 6 ± 10 Since the PDE type 6 isoenzyme has nearly a 60% amino acid similarity with that of PDE type 5, this protein is a likely target for sildena®l at higher doses. Other than PDE type 5, sildena®l has the highest af®nity for PDE type 6 amongst the other known PDE subtypes. 11 It has been suggested that uninterrupted, daily use of this medication for both men and women may provide prophylaxis against sexual dysfunction. However, no information has been published to support this dosage regimen. The safety pro®le of the uninterrupted use of sildena®l has not been evaluated as it pertains to alteration of PDE type 6 in the retina. In the present study we investigated whether exposure to a variety of sildena®l doses and dosage intervals affect the expression of an enzyme important in the phototransduction cascade.
Materials and methods

Animal experiment design
Male Sprague ± Dawley (SD) rats, 120 days old, were used. A total of 14 rats were randomized into different pellet dosage groups and duration of sildena®l exposure. The mean body weight of the rats at the time of sacri®ce was 433 g AE 41. All rats were orchiectomized, and a 2 cm testosterone stick was placed subcutaneously in the lower back. This method is employed in order to alleviate any potential postoperative hormonal¯uctuations. 12 At the time of operation a matrix-driven sustainedrelease sildena®l or placebo pellet (Innovative Research of America, Sarasota, Florida) was implanted subcutaneously into the upper back. Sustained-daily-release pellets of 1, 5, 10, 100, and 200 mg total dose of sildena®l were used. Each matrix-driven pellet was a 30-day release formulation designed to deliver equally divided daily portions until completion of the entire dose. The estimated amount of drug released each day is presented in Table 1 . Animals were sacri®ced 7 (1 week), 14 (2 weeks), and 29 days (4 weeks) after implantation. Sacri®ce was timed for all groups to be within the 30-day window of active pellet delivery of drug. All harvested retinal tissue was immediately snap frozen in liquid nitrogen. Each experimental time group (1 week, 2 weeks, and 4 weeks) had a control-matched animal with a placebo matrix pellet.
Serum sildena®l levels
At the time of sacri®ce, serum was collected from each animal. Sildena®l and its active metabolite UK-103,320 were assayed (P®zer Laboratories, Sandwich, Kent) in order to assure each animal had an active level of drug up until the time of sacri®ce. The levels of the active metabolite UK-103,320 were included because it has similar potency to sildena®l, and may contribute to the pharmacologic effects seen with the parent drug. 13 
RNA isolation
RNA was extracted and puri®ed from retinal tissue using the Tri Reagent protocol (Trizol, Molecular Research Center, Cincinnati, Ohio). RNA was precipitated with cold isopropanol and placed at À70 C overnight. The RNA was then spun at 14 000 rpm for 15 min, and the pellet was washed twice with cold ethanol. The pellet was resuspended in 50 mL of autoclaved water.
DNAse treatment
Each sample was treated with RQ1 DNAse (Promega Laboratories, Madison, WI) and incubated in a 37 C water bath for 30 min. RNA was recovered after equal volume phenolXcholoroform treatment, and subsequent equal volume chloroform recovery. The RNA solution was then buffered with 3 m sodium acetate, added to 100% ethanol and allowed to precipitate at À80 C for 30 min. The RNA was spun at 14 000 rpm for 15 min, and the pellet was washed with 70% ethanol. The pellet was resuspended in 25 mL of autoclaved water. All prepared RNA was checked for DNA contamination through the reverse transcriptase (RT)-polymerase chain reaction (PCR) (Perkin-Elmer, Norwalk, CT).
RT-PCR
After DNAse treatment, RT was performed on total retinal RNA using the murine leukemia virus (MuLV). The mixture of 1 mg retinal RNA with 0.5 mL MuLV was incubated at 42 C for 30 min, 99 C for 5 min, and 4 C for 5 min. The 10 mL RT mixture was then added to a total of 40 mL master mix of PCR reagents (0.5 mL Taq gold Polymerase (Perkin Elmer), 1 mL of each primer, and 2 mLMgCl). The following primers were used: Quantitative non-radioactive RT-PCR (Gene Amp PCR core Kit, Perkin-Elmer) consisted of an incubation period of 2 min at 95 C followed by successive cycles of 1 min 95 C, 1 min 60 C, and 1 min 72 C using a MJ Research thermocycler (model PTC-100). Samples were removed from the thermocycler at cycles 22 and 24 and left at 4 C overnight. Each 40 mL sample was then run on a 1.5% agarose (Sigma; wide rangeastandard 3:1) gel with 0.5 mgamL ethidium bromide at 120 V (Bio-Rad). The cDNA bands were then quanti®ed through densitometry using the Kodak 1D Image Analysis Software (Rochester, NY). The methods of Siebert et al 14 and Podlasek et al 15 were used for quantitation of the gene products. The log of density vs cycle number was plotted for both glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and PDE type 6. This was done in order to ®nd both the linear range and the ratio of all products for both reactions. This RT-PCR method quantitates measurement of PDE type 6 expression relative to our internal standard, GAPDH. The modi®ed method is independent of input RNA. The y-intercepts from the liner regions of semilogarithmic plots of the PCR product vs speci®c cycle number were then used as measures of the levels of PDE type 6 cDNA relative to that of GAPDH cDNA. All RNA from experimental-and placebo-matched groups were run in triplicate with standard error of the mean calculated for each result.
Statistics
The ANOVA test was used to analyze all densitometry values for comparing the treatment group with placebo. Statistical signi®cance was indicated when P`0.05.
Results
Sildena®l treatment group
PCR expression of PDE type 6 and the internal standard GAPDH, completed to 35 cycles, is shown in Figure 1 . In rats treated for 1 week, upregulation of PDE type 6 expression occurred with both the 1 mg and 5 mg pellet (P`0.02). We noted no such change in PDE type 6 as compared to placebo rats treated with 10 mg (P NS (not signi®cant)) for the same time period (Figure 2 ). Two weeks after sildena®l exposure, downregulation of PDE type 6 expression occurred at both the 100 mg (P`0.02) and the 200 mg (P`0.002) pellet doses ( Figure 3) .
In rats treated for 4 weeks, expression of PDE type 6 was not altered at the 1 mg formulation (P NS). However, at the 5 mg dose, signi®cant upregulation of PDE type 6 expression was demonstrated (P`0.05). There was signi®cant downregulation of PDE type 6 expression for all animals in the 4-week group given !10 mg pellets (P`0.01) (Figure 4) .
All animals treated in this study had active serum levels for both sildena®l and the active metabolite UK-103, 320 (data not shown). Figure 1 Ethidium bromide stained gel of RT-PCR products following ampli®cation of PDE type 6 (Lane 1) and GAPDH (Lane 2) in the rat retina. Lane 3 consists of both PDE type 6 and GAPDH. In this gel RT-PCR ampli®cation was completed in 35 cycles. PDE type 6 and GAPDH gene products are 274 and 380 bp, respectively, as expected. (*bp base pairs.) Figure 2 Mean PDE type 6 expression with one-week exposure to sildena®l. Bar graph representing the dose-dependent downregulation of PDE type 6 expression compared to placebo controls in rats sacri®ced within two weeks. The 7-day animals are compared to their time-matched placebo. PDE type 6 expression was calculated as the ratio of the optical density of the PDE6 band and the internal standard, GAPDH band. Error bars represent the SEM. (*P`0.02, ANOVA with P`0.05 the point of signi®cance.)
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Discussion
Signi®cant upregulation of PDE type 6 expression was observed with the 1 and 5 mg pellet dosages after 1 week of treatment. In the 4-week treatment group the animal given 5 mg demonstrated signi®-cant upregulation of PDE type 6 expression, while the 1 mg animal demonstrated a trend towards upregulation of PDE type 6 expression. The average daily dosage delivered from the 1 and 5 mg pellets over both time intervals (weeks 1 and 4) is shown in Table 1 . For the 5 mg pellet animals, a similar daily dosage was delivered (0.17 mgaday), yet over a different time period (1 vs 4 weeks) . Signi®cant upregulation of PDE type 6 expression occurred, regardless of the treatment length at the 5 mg dosage. At 1 mg a similar observation was made, yet the 4-week group showed only a trend towards upregulation.
At the 10 mg pellet dosage a different observation was noticed. Both animals received an average daily dose of 0.34 mgaday, yet the 1-week rat demonstrated a trend towards upregulation; whereas the 4-week rat demonstrated signi®cant downregulation of PDE type 6 expression. It appeared from these two dose-matched animals that the duration of sildena®l treatment (1 week vs 4 weeks), and not the actual daily dose was responsible for the downregulation of PDE type 6 expression.
Signi®cant dose-dependent downregulation of PDE type 6 expression occurred in all animals at pellet doses ! 100 mg, regardless of the duration of sildena®l treatment (2 vs 4 weeks). In the 4-week treatment group the downregulation of PDE type 6 expression was profound, starting at a pellet dose of 10 mg. This downregulation was more pronounced over each increase in pellet dose.
It appears from these data that both a dosage and time threshold may exist for the downregulation of PDE type 6 expression. Possibly, an accumulative saturation of PDE type 6 occurs at higher daily sildena®l dosages; however, this dosage threshold appears to be lowered the longer the treatment course. The rod photoreceptor cells may initially upregulate PDE type 6 at low doses, or early in the course of uninterrupted treatment. However, if the sildena®l dosage is high (average daily dose ! 3.4 mgaday) or the photoreceptor cells are exposed to the drug for a prolonged period of time (1 vs 4 weeks) downregulation of PDE type 6 occurs in the retina. Our study design did not include higher doses at 1 week or lower doses at 2 weeks duration of treatment. The ®ndings seem to indicate a doseand time-dependent downregulation of PDE type 6 expression exists with sildena®l in the rat retina. These ®ndings parallel previous animal studies where the dose-related effect of sildena®l caused retinal hyperpolarization in response to light. 1 It was hypothesized from these data that inhibition of PDE type 6 was the cause for the observed retinal hyperpolarization.
In humans a higher incidence of adverse visual effects occur in patients taking a ®xed sildena®l dosage ! 100 mg. Recent data reveal that there may be acute, yet reversible, retinal side effects in patients taking just a single dose of 100 mg of sildena®l. 16 The authors in this study concluded that inhibition of rod photoreceptor PDE type 6 was Figure 3 Mean PDE type 6 expression with two weeks exposure to sildena®l. Bar graph representing the dose-dependent downregulation of PDE type 6 expression compared to placebo controls in rats sacri®ced within two weeks. The 14-day animals are compared to their time-matched placebo. PDE type 6 expression was calculated as the ratio of the optical density of the PDE6 band and the internal standard, GAPDH band. Error bars represent the SEM. (**P`0.02, ***P`0.002, ANOVA with P`0.05 the point of signi®cance.) Figure 4 Mean PDE type 6 expression with four-week exposure to sildena®l. Bar graph representing the dose-dependent downregulation of PDE type 6 expression compared to placebo controls in rats sacri®ced at 29 days (four-week group). PDE type 6 expression was calculated as the ratio of the optical density of the PDE6 band and the internal standard, GAPDH band. Error bars represent the SEM. (*P`0.05, **P`0.01, ***P`0.008, ****P`0.002, ANOVA with P`0.05 the point of signi®cance).
the most likely mechanism. There also appears to be a dose-dependent relationship of adverse visual events with increasing dosage of sildena®l in humans. Men on acute sildena®l dosages of 100 mg experienced a 9 ± 11% incidence of adverse visual effects; however, those on a dose of 200 mg experienced a 40% incidence. It is uncertain whether our ®ndings of downregulation of retinal PDE type 6 expression from high dose or long term exposure to sildena®l can be extrapolated to human physiology.
All treated animals in this study had active serum sildena®l and UK-103,320 levels. As these serum levels represent a measurement at the end of treatment, they may not represent the average daily dose each animal received. Correlating the serum bioavailability of sildena®l and UK-103,320 levels with any type of therapeutic response would be unfounded as there are no data on this subject in the rat. The only conclusion that can be made concerning these serum levels is that active drug was available at the predetermined end of sildena®l treatment. Some error may exist in the particular pellet delivery system we used; however the strati®cation of PDE type 6 downregulation in the higher dose animals is highly signi®cant, which suggests a logical or systematic bioavailability of drug was present. Previous studies have supported the reliability of the sustained-release pellet system used in our design. The in-vivo, subcutaneous pellet delivery of epidermal growth factor, estrogen, clonidine, and a variety of calcium channel antagonists have all been successfully demonstrated in rats. 10,17 ± 21 The use of sildena®l pellets has not been previously documented. However, clonidine, a drug with physical chemistry characteristics similar to sildena®l, have all been successfully used in this manner. Clonidine sustained-release pellets were used to successfully treat hypertensive rats over a 3-week period. 17 Morphologic and biochemical differences between rod photoreceptor cell structure and function from rat to human are minimal. 7 Many inherited degenerative diseases of the retina in vertebrates, including human retinitis pigmentosa, have been associated with some type of mutation, absence, or defect involving one of the catalytic subunits of the rod-speci®c PDE type 6. 6,9,10,22 ± 26 Dysfunction of the PDE type 6 protein invariably leads to elevated retinal cGMP levels, subsequent accumulation of cGMP, and eventual rod photoreceptor degeneration. Models of human retinal PDE type 6 dysfunction or deletion demonstrate risk for severe retinopathy, and potential loss of vision. The time frame from initiation of these events until total loss of vision is not known. Our ®ndings indicate that a dose-dependent downregulation of PDE type 6 expression occurs in the rat retina with chronic sildena®l use. In our model, higher daily dose sildena®l caused profound and consistent downregulation of PDE type 6 expression within one month. Whether this information can be extrapolated to protein expression or to the human scenario is beyond the aim and conclusions of our study. Regardless, the advocacy of chronic sildena®l usage for prophylaxis against or treatment of erectile dysfunction has the potential for retinal damage and should be discouraged pending additional human trials. This study is the ®rst to document a sustained downregulation of PDE type 6 expression by sildena®l. The physiologic consequences of this are the subject of further experimentation.
Conclusion
Sildena®l downregulates rat retinal PDE type 6 expression in a dose-and time-dependent fashion. Sildena®l upregulates rat retinal PDE type 6 expression when given at low doses over a short period of time.
